These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1196 related items for PubMed ID: 8458110

  • 1. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
    DeWood MA, Kurnik PB, Jolly MK, Jain AC, Khaja F, Gorfinkel HJ, Morris DL, Satler L, LittleJohn J.
    Clin Cardiol; 1993 Apr; 16(4):302-10. PubMed ID: 8458110
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
    Arnold AE, Brower RW, Collen D, van Es GA, Lubsen J, Serruys PW, Simoons ML, Verstraete M.
    J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
    [Abstract] [Full Text] [Related]

  • 4. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, Uhlich F, Hauck S, Jost S, Rafflenbeul W, Lichtlen PR, Dietz R.
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [Abstract] [Full Text] [Related]

  • 5. Myocardial infarct artery patency and reocclusion rates after treatment with duteplase at the dose used in the International Study of Infarct Survival-3. Burroughs Wellcome Study Group.
    Kalbfleisch JM, Kurnik PB, Thadani U, DeWood MA, Kent R, Magorien RD, Jain AC, Spaccavento LJ, Morris DL, Taylor GJ.
    Am J Cardiol; 1993 Feb 15; 71(5):386-92. PubMed ID: 8430624
    [Abstract] [Full Text] [Related]

  • 6. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
    Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W.
    J Am Coll Cardiol; 1992 Apr 15; 19(5):885-91. PubMed ID: 1552106
    [Abstract] [Full Text] [Related]

  • 7. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V.
    J Am Coll Cardiol; 1995 Aug 15; 26(2):374-9. PubMed ID: 7608437
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
    Malcolm AD, Keltai M, Walsh MJ.
    Eur Heart J; 1996 Oct 15; 17(10):1522-31. PubMed ID: 8909909
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M.
    J Am Coll Cardiol; 1992 Sep 15; 20(3):513-9. PubMed ID: 1512327
    [Abstract] [Full Text] [Related]

  • 12. Enhanced myocardial salvage by maintenance of microvascular patency following initial thrombolysis with recombinant tissue plasminogen activator.
    Longridge DJ, Follenfant MJ, Maxwell MP, Ford AJ, Hughes B.
    Cardiovasc Res; 1990 Sep 15; 24(9):697-706. PubMed ID: 2121357
    [Abstract] [Full Text] [Related]

  • 13. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
    Brener SJ, Zeymer U, Adgey AA, Vrobel TR, Ellis SG, Neuhaus KL, Juran N, Ivanc TB, Ohman EM, Strony J, Kitt M, Topol EJ.
    J Am Coll Cardiol; 2002 Feb 06; 39(3):377-86. PubMed ID: 11823073
    [Abstract] [Full Text] [Related]

  • 14. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte.
    von Essen R, Zeymer U, Tebbe U, Jessel A, Kwasny H, Mateblowski M, Niederer W, Wagner J, Mäurer W, von Leitner ER, Haerten K, Roth M, Neuhaus KL.
    Coron Artery Dis; 1998 Feb 06; 9(5):265-72. PubMed ID: 9710686
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters.
    Koster RW, van Stralen R, McNeill AJ, Adgey AA, Fox KA, Dymond D, Sponzilli C, Jewitt D, Bucknall C, Kluft C.
    Eur Heart J; 1990 Aug 06; 11(8):730-9. PubMed ID: 2118853
    [Abstract] [Full Text] [Related]

  • 17. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM, Bahr RD, Flaherty JT, Gurewich V, Levine HJ, Loscalzo J, Schumacher RR, Topol EJ, Wahr DW, Braunwald E.
    Am J Cardiol; 1991 Dec 15; 68(17):1564-9. PubMed ID: 1746455
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
    Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D.
    Circulation; 1995 Oct 15; 92(8):2044-9. PubMed ID: 7554180
    [Abstract] [Full Text] [Related]

  • 20. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
    Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT.
    Ann Intern Med; 1991 Aug 15; 115(4):256-65. PubMed ID: 1906692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.